Granted Patent
B2
US 12,577,568 · App. 17/782,848 · Granted Mar 17, 2026
Methods for controlling extracorporeal membrane oxygenation (ECMO) coagulation
Inventors:
Bruce Sullenger (Durham, NC); Elisabeth Tracy (Durham, NC); Christopher Reed (Durham, NC)
Assignee:
Duke University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application provides for a method for controlling coagulation in a subject in need of extracorporeal membrane oxygenation. The method comprises administering an effective amount of an anticoagulant agent that directly inhibits one or more steps in a coagulation pathway to the subject, wherein the effective amount of the anticoagulant agent is capable of controlling coagulation during extra corporeal membrane oxygenation for a coagulation control time of at least 4 hours.
Claims (15)
1 . A method for controlling coagulation in a subject in need of extracorporeal membrane oxygenation, the method comprising administering an effective amount of an anticoagulant agent that directly inhibits one or more steps in a coagulation pathway to the subject, wherein the effective amount of the anticoagulant agent is administered as a bolus and controls coagulation during extra corporeal membrane oxygenation for a coagulation control time of at least 4 hours and wherein the anticoagulant agent is an anticoagulant aptamer comprising an oligonucleotide having at least 80% sequence identity to any one of SEQ ID NOS: 1-3.
2 . The method of claim 1 further comprising administering a second effective amount of the anticoagulant agent to the subject after the coagulation control time.
3 . The method of claim 2 , wherein the subject does not receive an administration of the anticoagulant agent during the coagulation control time.
4 . The method of claim 2 , wherein the second effective amount of the anticoagulant agent is administered as a bolus.
5 . The method of claim 1 , further comprising prior to administering the anticoagulant agent to the subject determining whether the subject has hypersensitivity to the anticoagulant agent or a component thereof.
6 . The method of claim 1 , wherein the anticoagulant aptamer is PEGylated.
7 . The method of claim 1 , wherein the anticoagulant aptamer comprises the oligonucleotide of SEQ ID NO: 1.
8 . The method of claim 1 , wherein the coagulation control time is characterized by one or more of the following: hematocrit stability, absence of a need for blood transfusion, clinical evidence of hemostasis, absence of clinical signs of bleeding, negligible extracorporeal transmembrane oxygenator pressure gradient, or stable blood flows through the extracorporeal membrane oxygenator.
9 . The method of claim 1 , wherein the subject is a pediatric subject.
10 . The method of claim 1 , wherein the subject is in need of a treatment for cardiopulmonary failure.
11 . The method of claim 1 , wherein the subject is in need of a treatment for a severe acute respiratory syndrome.
12 . The method of claim 11 , wherein the subject has SARS-COV-2 infection.
13 . The method of claim 1 , wherein the anticoagulant agent comprises an aptamer that inhibits one of more steps in the contact coagulation pathway.
14 . The method of claim 1 , wherein the anticoagulant agent inhibits one of more of Factor IX, Factor X, Factor XI, Factor XII, or an activated form thereof.
15 . The method of claim 1 , wherein the anticoagulant agent comprises DTRI-178.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 18, 2025
From: SULLENGER, BRUCE; TRACY, ELISABETH; REED, CHRISTOPHER
To: DUKE UNIVERSITY
Reel/Frame 073262/0975 →
Continuity (2)
Provisional Application
62943304
· Dec 4, 2019
References Cited (118)
US 5670637A
· Gold et al.
· 1997
[cited by applicant]
US 5854038A
· Sullenger et al.
· 1998
[cited by applicant]
US 7300922B2
· Sullenger et al.
· 2007
[cited by applicant]
US 7304041B2
· Rusconi
· 2007
[cited by applicant]
US 7312325B2
· Sullenger et al.
· 2007
[cited by applicant]
US 7396664B2
· Daly et al.
· 2008
[cited by applicant]
US 7566701B2
· Diener et al.
· 2009
[cited by applicant]
US 7741307B2
· Sullenger et al.
· 2010
[cited by applicant]
US 7776836B2
· Sullenger et al.
· 2010
[cited by applicant]
US 8367627B2
· Sullenger et al.
· 2013
[cited by applicant]
US 8790924B2
· Sullenger et al.
· 2014
[cited by applicant]
US 9061043B2
· Sullenger et al.
· 2015
[cited by applicant]
US 9340591B2
· Sullenger et al.
· 2016
[cited by applicant]
US 9687529B2
· Sullenger et al.
· 2017
[cited by applicant]
US 9873727B2
· Sullenger et al.
· 2018
[cited by applicant]
US 20050176940A1
· King
· 2005
[cited by applicant]
US 20090048193A1
· Rusconi et al.
· 2009
[cited by applicant]
US 20110197292A1
· Sullenger et al.
· 2011
[cited by applicant]
US 20120040373A1
· Ubeda
· 2012
[cited by applicant]
US 20120149764A1
· Diener
· 2012
[cited by applicant]
US 20150247147A1
· Rusconi
· 2015
[cited by applicant]
US 20150322425A1
· Sullenger et al.
· 2015
[cited by applicant]
WO 1991019813
· 1991
[cited by applicant]
WO 2007035532
· 2007
[cited by applicant]
WO WO2007140000A2
· 2007
[cited by examiner]
Helms et al. J Throm Haemost. 21: pp. 373-396 (Year: 2023).
[cited by examiner]
Netley et al. J Extra Corpor Technol Sep. 2018;50:161-6 (Year: 2018).
[cited by examiner]
Ang et al. Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation—a single centre experience. Vox Sanguinis, Jan. 2009…
[cited by applicant]
Arepally. Heparin-induced thrombocytopenia. Blood. May 2017;129(21):2864-2872.
[cited by applicant]
Bagge et al. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. Blood Coagulation & Fibrinolysis. Apr. 1994;5(2):265-272.
[cited by applicant]
Barbaro et al. Pediatric Extracorporeal Life Support Organization Registry International Report 2016. ASAIO Journal. Jul./Aug. 2017; 63(4):456-463.
[cited by applicant]
Bartlett et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO Journal. May 2020;66(5):472-474.
[cited by applicant]
Bateman et al. Anemia, blood loss, and blood transfusions in North American children in the intensive care unit. Am Journal of Respir Crit Care Med. Jul. 2008;178(1):26-33.
[cited by applicant]
Bel et al. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. European Journal of Cardio-Thoracic Surgery. Feb. 2015;49(2):682-689.
[cited by applicant]
Bompiani et al. Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chemistry & Biology. Aug. 2014;21(8):935-944.
[cited by applicant]
Buddai et al. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. Journal of Biological Chemistry. Feb. 2010;285(8):5212-5223.
[cited by applicant]
Cashen et al. Platelet Transfusion Practice and Related Outcomes in Pediatric Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med. Feb. 2020;21(2):178-185.
[cited by applicant]
Chabata et al. Emerging applications of aptamers for anticoagulation and hemostasis. Curr Opin Hematol. Sep. 2018;25(5):382-388.
[cited by applicant]
Chan et al. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. Journal of Thrombosis & Haemostasis. May 2008;6(5):789-796.
[cited by applicant]
Chan et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. Jun. 2008;117(22):2865-2874.
[cited by applicant]
Dyke et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activ…
[cited by applicant]
European Patent Office, Extended European Search Report for EP Application 20896722.4 mailed Jul. 29, 2024. 12 pages.
[cited by applicant]
Extracorporeal Life Support Organization (ELSO). ECLS Registry Report—International Summary. Jul. 2019. Accessed Nov. 11, 2019, from https://www.elso.org/Registry/Statistics/InternationalSummary.aspx.
[cited by applicant]
Gaffney et al. Extracorporeal life support. BMJournal. Nov. 2010;341:c5317.
[cited by applicant]
Gopinath et al. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway. Thrombosis and Haemostasis. 2006;95(5):767-771.
[cited by applicant]
Groenen et al. Analyses of pig genomes provide insight into porcine demography and evolution. Nature. Nov. 2012;491(7424):393-398.
[cited by applicant]
Gunaratne et al. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology. Aug. 2018;36(7):606-613.
[cited by applicant]
Helms et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. Jun. 2020;46(6):1089-1098.
[cited by applicant]
Heman-Ackah et al. Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series. Neurosurgery. Aug. 2020;87(2):E147-E151.
[cited by applicant]
Hoffman et al. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood. 1995;86(5):1794-1801.
[cited by applicant]
International Searching Authority, International Search Report and Written Opinion for International Patent Application No. PCT/US2020/063389, dated Mar. 23, 2021. 11 pages.
[cited by applicant]
Jacobs et al. Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients. ASAIO Journal. Jul. 2020;66(7):722-730.
[cited by applicant]
Klok et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis Research. Jul. 2020;191:148-150.
[cited by applicant]
Köstering et al. Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Goettingen breed). Laboratory Animals. 1983;17(4):346-349.
[cited by applicant]
Kuhle et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica. Apr. 2007;92(4):554-557.
[cited by applicant]
Kurundkar et al. Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn piglet. Pediatr Res. Aug. 2010;68(2):128-133.
[cited by applicant]
Larsson et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. Feb. 2014;6(222):222ra17.
[cited by applicant]
Layzer and Sullenger. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides. Mar. 2007;17(1):1-11.
[cited by applicant]
Lelovas et al. A comparative anatomic and physiologic overview of the porcine heart. Journal of Am Assoc Lab Anim Sci. Sep. 2014;53(5):432-438.
[cited by applicant]
Lequier et al. ELSO Anticoagulation Guideline. 2014. Accessed Apr. 6, 2020, from: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf.
[cited by applicant]
Levy et al. Antithrombin: anti-inflammatory properties and clinical applications. Thrombosis and Haemostasis. 2016;115(4):712-728.
[cited by applicant]
Lunney. Advances in swine biomedical model genomics. Int Journal of Biol Sci. Feb. 2007;3(3):179-184.
[cited by applicant]
Maclaren et al. Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation. JAMA. Apr. 2020;323(13):1245-1246.
[cited by applicant]
Makdisi and Wang. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. Journal of Thorac Dis. 2015;7(7):E166-E176.
[cited by applicant]
Massicotte et al. A comparative study of coagulation systems in newborn animals. Pediatr Res. 1986;20(10):961-965.
[cited by applicant]
May et al. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis. Br Journal of Haematol. Jun. 2016;173(5):769-778.
[cited by applicant]
Millar et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. Dec. 2016;20(1):387.
[cited by applicant]
Mittermayr et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br Journal of Anaesth. 2005;95(3):310-316.
[cited by applicant]
Mohankumar et al. Intestinal epithelial apoptosis initiates gut mucosal injury during extracorporeal membrane oxygenation in the newborn piglet. Lab Invest. 2014;94(2):150-160.
[cited by applicant]
Münster et al. Usefulness of human coagulation and fibrinolysis assays in domestic pigs. Comp Med. Feb. 2002;52(1):39-43.
[cited by applicant]
National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: Extracorporeal Membrane Oxygenation. Apr. 2020. Accessed Jun. 21, 2020, from https://covid19treatmentguidelines.nih.gov/crit…
[cited by applicant]
Nellenbach et al. Comparison of Neonatal and Adult Fibrin Clot Properties between Porcine and Human Plasma. Anesthesiology. May 2020;132(5):1091.
[cited by applicant]
Nimjee et al. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther. Sep. 2006;14(3):408-415.
[cited by applicant]
Nimjee et al. Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol. Jan. 2017;57(1):61-79.
[cited by applicant]
Nimjee et al. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Mol Ther. Jul. 2019;27(7):1228-1241.
[cited by applicant]
Nimjee et al. Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Ther. Jun. 2016;26(3):147-155.
[cited by applicant]
Noubouossie et al. Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood. 2020;135(10):755-765.
[cited by applicant]
Nugent. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci U S A. Sep. 2000;97(19):10301-10303.
[cited by applicant]
Olsen et al. The pig as a model in blood coagulation and fibrinolysis research. Scandinavian Journal of Laboratory Animal Sciences. Dec. 1999;26(4):10.
[cited by applicant]
Oney et al. Development of universal antidotes to control aptamer activity. Nature Medicine. Oct. 2009;15(10):1224-1228.
[cited by applicant]
Ontaneda and Annich. Novel Surfaces in Extracorporeal Membrane Oxygenation Circuits. Frontiers in Medicine (Lausanne). Nov. 2018;5:321.
[cited by applicant]
Paden et al. Extracorporeal Life Support Organization Registry Report 2012. ASAIO Journal. May 2013;59(3):202-210.
[cited by applicant]
Pfohler et al. Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients. World Allergy Organ Journal. Dec. 2008;1(12):194-199.
[cited by applicant]
Pireaux et al. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. Journal of Am Coll Cardiol. Oct. 2019;74(17):2178-2189.
[cited by applicant]
Reed et al. Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO, Molecular Therapy-Nucleic Acids. 2022;27:524-534.
[cited by applicant]
Reed et al. Coagulopathy Characterized by Rotational Thromboelastometry in a Porcine Pediatric ECMO Model. Journal of Extra Corpor Technol. Sep. 2020;52(3):203-211.
[cited by applicant]
Rusconi et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. Sep. 2002;419(6902):90-94.
[cited by applicant]
Sanfilippo et al. Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review. Journal of Intensive Care Med. Jun. 2017;32(5):312-319.
[cited by applicant]
Schindelin et al. Fiji: an open-source platform for biological-image analysis. Nature Methods. Jul. 2012;9(7):676-682.
[cited by applicant]
Slaughter et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. Journal of Heart Lung Transplant. Jul. 2013;32(7):675-683.
[cited by applicant]
Stafford. Extravascular FIX and coagulation. Thrombosis Journal. 2016;14(Suppl 1):35.
[cited by applicant]
Stern et al. In vivo evidence of intravascular binding sites for coagulation factor IX. British Journal of Haematology. Jun. 1987;66(2):227-232.
[cited by applicant]
Sullenger et al. Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. Journal of Biol Chem. Apr. 2012;287(16):12779-12786.
[cited by applicant]
Sutter et al. Acute Neurologic Complications During Extracorporeal Membrane Oxygenation: A Systematic Review. Crit Care Med, Sep. 2018;46(9):1506-1513.
[cited by applicant]
Sy et al. Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis. Journal of Crit …
[cited by applicant]
Tanaka et al. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thrombosis and Haemostasis. 2009; 101(05):827-833.
[cited by applicant]
Tang et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. Apr. 2020;18(4):844-847.
[cited by applicant]
Toulon et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thrombosis and Haemostasis. 2016;116(07):9-16.
[cited by applicant]
Tuerk and Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. Aug. 1990;249(4968):505-510.
[cited by applicant]
Walchak et al. Simple blood typing and cross matching techniques in swine. Lab Anim (NY). Oct. 2016;45(10):366-368.
[cited by applicant]
Walker and Royston. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br Journal of Anaesth. Jun. 2002;88(6):848-863.
[cited by applicant]
Werho et al. Hemorrhagic complications in pediatric cardiac patients on extracorporeal membrane oxygenation: an analysis of the Extracorporeal Life Support Organization Registry. Pediatr Crit Care Med. Mar. 2015;16(3):2…
[cited by applicant]
Woodruff et al. Generation and characterization of aptamers targeting factor XIa. Thromb Res. Aug. 2017;156:134-141.
[cited by applicant]
Woodruff et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. Journal of Thrombosis and Haemostasis. Jul. 2013;11(7):1364-1373.
[cited by applicant]
Woodruff et al. The many faces of the contact pathway and their role in thrombosis. Journal of Thrombosis and Thrombolysis. Jul. 2011;32(1):9-20.
[cited by applicant]
Xanthos et al. Baseline hemodynamics in anesthetized landrace-large white swine: reference values for research in cardiac arrest and cardiopulmonary resuscitation models. Journal of Am Assoc Lab Anim Sci. Sep. 2007;46(5…
[cited by applicant]